[{"id":1,"entrez_name":"ABL1","entrez_id":25,"name":"BCR-ABL","description":"The BCR-ABL fusion protein, commonly referred to as the philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML), but despite its ability initiate disease in mice, its status an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response.","evidence_items":[{"id":1,"text":"Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"Schmidt et al., 2014, Leukemia","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/25212276","pubmed_id":"25212276","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":2,"evidence_level":"C","evidence_type":"Diagnostic","clinical_significance":"Positive","evidence_direction":"Does Not Support","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":2,"text":"The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"An et al., 2010, Leuk. Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20537386","pubmed_id":"20537386","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"A","evidence_type":"Diagnostic","clinical_significance":"Positive","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":3,"text":"The use of second-generation BCR-ABL targeted therapies has been effective in patients resistant to imatinib.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"An et al., 2010, Leuk. Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20537386","pubmed_id":"20537386","drugs":[{"id":2,"name":"Nilotinib","pubchem_id":null},{"id":3,"name":"Dasatinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]},{"id":3,"entrez_name":"ABL1","entrez_id":25,"name":"BCR-ABL E255K","description":"While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of seleciton have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.","evidence_items":[{"id":4,"text":"COS7 cell lines transfected with BCR/ABL constructs harboring E255K mutations were shown to be resistant to imatinib and exhibited increased kinase activity.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/15194504","pubmed_id":"15194504","drugs":[{"id":4,"name":"Imatinib","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[{"id":1,"name":"Imatinib Resistance","description":"While imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. "}]},{"id":2,"entrez_name":"ABL1","entrez_id":25,"name":"BCR-ABL T315I","description":"While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of seleciton have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.","evidence_items":[{"id":5,"text":"COS7 cell lines transfected with BCR/ABL constructs harboring T315I mutations were shown to be resistant to imatinib and exhibited increased kinase activity.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/15194504","pubmed_id":"15194504","drugs":[{"id":4,"name":"Imatinib","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":6,"text":"In chronic myeloid leukemia patients with the ABL T315I mutation, tumors have shown to be resistant to imatinib treatment.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"An et al., 2010, Leuk. Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20537386","pubmed_id":"20537386","drugs":[{"id":4,"name":"Imatinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[{"id":1,"name":"Imatinib Resistance","description":"While imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. "}]},{"id":4,"entrez_name":"AKT1","entrez_id":207,"name":"E17K","description":"AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase ihibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.","evidence_items":[{"id":7,"text":"PIK3CA mutation, but not AKT1 E17K, has been shown to confer sensitiity to the AKT inhibitor MK-2206 in breast cancer cell lines.","disease":"Breast Cancer","doid":"1612","citation":"Beaver et al., 2013, Clin. Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23888070","pubmed_id":"23888070","drugs":[{"id":5,"name":"MK-2206","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Does Not Support","variant_hgvs":"14:105246551-105246551 (C-\u003eT)","variant_origin":"Somatic"}],"variant_groups":[]},{"id":5,"entrez_name":"ALK","entrez_id":238,"name":"EML4-ALK","description":"The EML4-ALK fusion has been seen in non-small cell lung cancer, and appears to be an alternative mechanism for ALK activation. Cells with this fusion have been shown to be sensitive to the ALK inhibitor crizotinib.","evidence_items":[{"id":8,"text":"In patients with non-small cell lung cancer harboring the EML4-ALK fusion, treatment with crizotinib has shown to be effective in acheiving stable disease.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Choi et al., 2010, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20979473","pubmed_id":"20979473","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[{"id":2,"name":"ALK Fusions","description":"ALK fusion positive non-small cell lung cancer (NSCLC) is treated as its own subset of NSCLC. Many ALK fusions that have been seen as recurrent in cancer serve to increase the activity of the ALK oncogene relative to normal cells. While EML4 is the most common fusion partner, other 5' partners have been observed. The EML4-ALK fusion has shown sensitivity to targeted tyrosine kinase inhibitors such as crizotinib. "}]},{"id":6,"entrez_name":"ALK","entrez_id":238,"name":"EML4-ALK C1156Y","description":"In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.","evidence_items":[{"id":9,"text":"In patients with non-small cell lung cancer harboring EML4-ALK fusion, the C1156Y variant has been shown to confer resistance to crizotinib.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Choi et al., 2010, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20979473","pubmed_id":"20979473","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[{"id":3,"name":"Crizotinib Resistance","description":"The ALK oncogene has long been considered a driving factor in non-small cell lung cancer (NSCLC). The targeted tyrosine kinase inhibitor criztonib has shown to be effective in ALK-mutant NSCLC. However, in patients that have shown acquired resistance to crizotinib, missense mutations in the tyrosine kinase domain have shown to drive this resistance. "},{"id":2,"name":"ALK Fusions","description":"ALK fusion positive non-small cell lung cancer (NSCLC) is treated as its own subset of NSCLC. Many ALK fusions that have been seen as recurrent in cancer serve to increase the activity of the ALK oncogene relative to normal cells. While EML4 is the most common fusion partner, other 5' partners have been observed. The EML4-ALK fusion has shown sensitivity to targeted tyrosine kinase inhibitors such as crizotinib. "}]},{"id":7,"entrez_name":"ALK","entrez_id":238,"name":"EML4-ALK L1196M","description":"In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.","evidence_items":[{"id":10,"text":"CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or AML4-ALK with the L1196M mutation","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Sakamoto et al., 2011, Cancer Cell","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21575866","pubmed_id":"21575866","drugs":[{"id":7,"name":"CH5424802","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":11,"text":"In patients with non-small cell lung cancer harboring EML4-ALK fusion, the L1196M variant has been shown to confer resistance to crizotinib.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Choi et al., 2010, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20979473","pubmed_id":"20979473","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[{"id":3,"name":"Crizotinib Resistance","description":"The ALK oncogene has long been considered a driving factor in non-small cell lung cancer (NSCLC). The targeted tyrosine kinase inhibitor criztonib has shown to be effective in ALK-mutant NSCLC. However, in patients that have shown acquired resistance to crizotinib, missense mutations in the tyrosine kinase domain have shown to drive this resistance. "},{"id":2,"name":"ALK Fusions","description":"ALK fusion positive non-small cell lung cancer (NSCLC) is treated as its own subset of NSCLC. Many ALK fusions that have been seen as recurrent in cancer serve to increase the activity of the ALK oncogene relative to normal cells. While EML4 is the most common fusion partner, other 5' partners have been observed. The EML4-ALK fusion has shown sensitivity to targeted tyrosine kinase inhibitors such as crizotinib. "}]},{"id":8,"entrez_name":"ALK","entrez_id":238,"name":"F1174L","description":"ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.","evidence_items":[{"id":12,"text":"Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.","disease":"Inflammatory Myofibroblastic Tumor","doid":"0050905","citation":"Sasaki et al., 2010, Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21030459","pubmed_id":"21030459","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":13,"text":"CH5424802 is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.","disease":"Neuroblastoma","doid":"769","citation":"Sakamoto et al., 2011, Cancer Cell","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21575866","pubmed_id":"21575866","drugs":[{"id":7,"name":"CH5424802","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":14,"text":"Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.","disease":"Neuroblastoma","doid":"769","citation":"Bresler et al., 2011, Sci Transl Med","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/22072639","pubmed_id":"22072639","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":15,"text":"High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.","disease":"Neuroblastoma","doid":"769","citation":"Heuckmann et al., 2011, Clin. Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21948233","pubmed_id":"21948233","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":16,"text":"SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition","disease":"Neuroblastoma","doid":"769","citation":"George et al., 2008, Nature","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/18923525","pubmed_id":"18923525","drugs":[{"id":8,"name":"TAE684","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":17,"text":"Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Sasaki et al., 2010, Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21030459","pubmed_id":"21030459","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"}],"variant_groups":[{"id":3,"name":"Crizotinib Resistance","description":"The ALK oncogene has long been considered a driving factor in non-small cell lung cancer (NSCLC). The targeted tyrosine kinase inhibitor criztonib has shown to be effective in ALK-mutant NSCLC. However, in patients that have shown acquired resistance to crizotinib, missense mutations in the tyrosine kinase domain have shown to drive this resistance. "}]},{"id":9,"entrez_name":"ALK","entrez_id":238,"name":"R1275Q","description":"ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This, and the geldanamycin deriviative 17-DMAG, has been shown to be effective in NSCLC cell lines.","evidence_items":[{"id":18,"text":"Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation","disease":"Neuroblastoma","doid":"769","citation":"Bresler et al., 2011, Sci Transl Med","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/22072639","pubmed_id":"22072639","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29432664-29432664 (C-\u003eT)","variant_origin":"Somatic"},{"id":19,"text":"TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L.","disease":"Neuroblastoma","doid":"769","citation":"George et al., 2008, Nature","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/18923525","pubmed_id":"18923525","drugs":[{"id":8,"name":"TAE684","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29432664-29432664 (C-\u003eT)","variant_origin":"Somatic"},{"id":20,"text":"The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.","disease":"Neuroblastoma","doid":"769","citation":"George et al., 2008, Nature","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/18923525","pubmed_id":"18923525","drugs":[{"id":8,"name":"TAE684","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29432664-29432664 (C-\u003eT)","variant_origin":"Somatic"}],"variant_groups":[]},{"id":10,"entrez_name":"ARAF","entrez_id":369,"name":"S214C","description":"ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.","evidence_items":[{"id":21,"text":"In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Imielinski et al., 2014, J. Clin. Invest.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24569458","pubmed_id":"24569458","drugs":[{"id":9,"name":"Sorafenib","pubchem_id":null}],"rating":2,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"X:47426121-47426121 (C-\u003eG)","variant_origin":"Somatic"},{"id":22,"text":"Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Imielinski et al., 2014, J. Clin. Invest.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24569458","pubmed_id":"24569458","drugs":[{"id":9,"name":"Sorafenib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"X:47426121-47426121 (C-\u003eG)","variant_origin":"Somatic"},{"id":23,"text":"Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Imielinski et al., 2014, J. Clin. Invest.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24569458","pubmed_id":"24569458","drugs":[{"id":10,"name":"Trametinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"X:47426121-47426121 (C-\u003eG)","variant_origin":"Somatic"}],"variant_groups":[]},{"id":17,"entrez_name":"BRAF","entrez_id":673,"name":"V600","description":"BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutation pages on the left sidebar.","evidence_items":[{"id":24,"text":"In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone)","disease":"Colorectal Cancer","doid":"9256","citation":"Peeters et al., 2013, Clin. Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23325582","pubmed_id":"23325582","drugs":[{"id":11,"name":"Panitumumab","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":25,"text":"Melanoma patients with BRAF V600E/K mutations had longer progression-free survival, increased tumor regression,  and increased duration of response to combined dabrafenib and trametinib treatment compared to dabrafenib alone","disease":"Melanoma","doid":"1909","citation":"Flaherty et al., 2012, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23020132","pubmed_id":"23020132","drugs":[{"id":12,"name":"Dabrafenib","pubchem_id":null},{"id":10,"name":"Trametinib","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":26,"text":"BRAF mutations are associated with melanoma arising in non-chronic sun damaged skin and with superficial spreading melanoma","disease":"Melanoma","doid":"1909","citation":"Lee et al., 2011, Br. J. Dermatol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21166657","pubmed_id":"21166657","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Diagnostic","clinical_significance":"Positive","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]},{"id":11,"entrez_name":"BRAF","entrez_id":673,"name":"V600D","description":"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.","evidence_items":[{"id":27,"text":"Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.","disease":"Melanoma","doid":"1909","citation":"Ponti et al., 2013, J. Clin. Pathol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23463675","pubmed_id":"23463675","drugs":[{"id":12,"name":"Dabrafenib","pubchem_id":null}],"rating":5,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"7:140453135-140453136 (CA-\u003eAT)","variant_origin":"Somatic"}],"variant_groups":[{"id":4,"name":"Other V600's","description":"While BRAF V600E is nearly ubiquitous in many cancer types, other V600 variants have also been observed and studied to a lesser degree. At first approximation, many of these variants seem to behave similarly to V600E, and treatment with dabrafenib has been shown to be effective. "}]},{"id":12,"entrez_name":"BRAF","entrez_id":673,"name":"V600E","description":"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, KRAS, and CDK2NA mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. While the drugs cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.","evidence_items":[{"id":28,"text":"Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.","disease":"Colorectal Cancer","doid":"9256","citation":"Di Nicolantonio et al., 2008, J. Clin. Oncol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/19001320","pubmed_id":"19001320","drugs":[{"id":13,"name":"Cetuximab","pubchem_id":null},{"id":11,"name":"Panitumumab","pubchem_id":null},{"id":9,"name":"Sorafenib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":29,"text":"Combined PD0325901 and PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation","disease":"Colorectal Cancer","doid":"9256","citation":"Rad et al., 2013, Cancer Cell","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23845441","pubmed_id":"23845441","drugs":[{"id":14,"name":"PD0325901","pubchem_id":null},{"id":15,"name":"PLX4720","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":30,"text":"Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy","disease":"Colorectal Cancer","doid":"9256","citation":"Ji et al., 2013, Clin. Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23812671","pubmed_id":"23812671","drugs":[{"id":15,"name":"PLX4720","pubchem_id":null},{"id":16,"name":"Nutlin-3","pubchem_id":null}],"rating":2,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":31,"text":"Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased survival and reduced tumor burden compared to single and double agent therapies.","disease":"Colorectal Cancer","doid":"9256","citation":"Yang et al., 2012, Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/22180495","pubmed_id":"22180495","drugs":[{"id":17,"name":"Capecitabine","pubchem_id":null},{"id":18,"name":"Vemurafenib","pubchem_id":null},{"id":19,"name":"Bevacizumab","pubchem_id":null}],"rating":2,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":32,"text":"Chemotherapy-refractory patients with colorectal cancer harboring BRAF mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype BRAF","disease":"Colorectal Cancer","doid":"9256","citation":"De Roock et al., 2010, Lancet Oncol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20619739","pubmed_id":"20619739","drugs":[{"id":13,"name":"Cetuximab","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":33,"text":"V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as a marker of poor prognosis.","disease":"Colorectal Cancer","doid":"9256","citation":"Chen et al., 2014, PLoS ONE","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24594804","pubmed_id":"24594804","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":5,"evidence_level":"A","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":34,"text":"Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation","disease":"Colorectal Cancer","doid":"9256","citation":"Yang et al., 2012, Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/22180495","pubmed_id":"22180495","drugs":[{"id":18,"name":"Vemurafenib","pubchem_id":null}],"rating":2,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":35,"text":"BRAF status does not predict prognosis in patients treated with dacarbazine or temozolomide.","disease":"Melanoma","doid":"1909","citation":"Meckbach et al., 2014, PLoS ONE","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24586605","pubmed_id":"24586605","drugs":[{"id":20,"name":"Dacarbazine","pubchem_id":null},{"id":21,"name":"Temozolomide","pubchem_id":null}],"rating":2,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"N / A","evidence_direction":"Does Not Support","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":36,"text":"Dabrafenib with trametinib provides higher response rate and lower toxicity-as compared to chemotherapy-in patients with melanoma.","disease":"Melanoma","doid":"1909","citation":"Menzies et al., 2014, Clin. Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24583796","pubmed_id":"24583796","drugs":[{"id":12,"name":"Dabrafenib","pubchem_id":null},{"id":10,"name":"Trametinib","pubchem_id":null}],"rating":5,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":37,"text":"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors.","disease":"Melanoma","doid":"1909","citation":"Nissan et al., 2014, Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24576830","pubmed_id":"24576830","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Does Not Support","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":38,"text":"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.","disease":"Melanoma","doid":"1909","citation":"Nissan et al., 2014, Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24576830","pubmed_id":"24576830","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":39,"text":"BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.","disease":"Melanoma","doid":"1909","citation":"Nagore et al., 2014, J. Am. Acad. Dermatol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24388723","pubmed_id":"24388723","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":40,"text":"In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Rudin et al., 2013, J Thorac Oncol","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23524406","pubmed_id":"23524406","drugs":[{"id":12,"name":"Dabrafenib","pubchem_id":null}],"rating":2,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":41,"text":"BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer","disease":"Thyroid Cancer","doid":"1781","citation":"Howell et al., 2011, Ann. Surg. Oncol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21594703","pubmed_id":"21594703","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Diagnostic","clinical_significance":"Positive","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":42,"text":"Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.","disease":"Thyroid Cancer","doid":"1781","citation":"Crescenzi et al., 2014, Horm. Metab. Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24570209","pubmed_id":"24570209","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":5,"evidence_level":"B","evidence_type":"Diagnostic","clinical_significance":"Positive","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":43,"text":"Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.","disease":"Thyroid Cancer","doid":"1781","citation":"Zhang et al., 2014, Diagn Pathol","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24588959","pubmed_id":"24588959","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":5,"evidence_level":"B","evidence_type":"Diagnostic","clinical_significance":"Positive","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":44,"text":"Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.","disease":"Thyroid Cancer","doid":"1781","citation":"Walczyk et al., 2014, Clin. Endocrinol. (Oxf)","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24354346","pubmed_id":"24354346","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":5,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Does Not Support","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":45,"text":"BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (\u003e65 yo) and younger (\u003c65 yo) cohorts.","disease":"Thyroid Cancer","doid":"1781","citation":"Howell et al., 2011, Ann. Surg. Oncol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21594703","pubmed_id":"21594703","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":46,"text":"BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.","disease":"Thyroid Cancer","doid":"1781","citation":"He et al., 2014, Oncol Lett","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24396464","pubmed_id":"24396464","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":47,"text":"V600E is correlated with disease recurrence in both age cohorts (\u003e65 and \u003c65 yo).","disease":"Thyroid Cancer","doid":"1781","citation":"Howell et al., 2011, Ann. Surg. Oncol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21594703","pubmed_id":"21594703","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453136 (A-\u003eT)","variant_origin":"Somatic"},{"id":406,"text":"\"From the screen, we discovered that proteasome inhibitors show selectivity toward BRAF V600Emutant cells, irrespective of PTEN or RB1 expression. Preferential targeting of BRAF-mutant cells by proteasome inhibitors was corroborated in a second BRAF V600E isogenic model, as well as in a panel of colorectal cancer cell lines by the use of the proteasome inhibitor carfilzomib. Notably, carfilzomib also showed striking in vivo activity in a BRAF-mutant human colorectal cancer xenograft model. Vulnerability to proteasome inhibitors is dependent on persistent BRAF signaling, because BRAF V600E blockade by PLX4720 reversed sensitivity to carfilzomib in BRAF-mutant colorectal cancer cells. Our findings indicated that proteasome inhibition might represent a valuable targeting strategy in BRAF V600Emutant colorectal tumors.\"","disease":"Colorectal Cancer","doid":"9256","citation":"Zecchin et al., 2013, Mol. Cancer Ther.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24107445","pubmed_id":"24107445","drugs":[{"id":67,"name":"Carfilzomib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]},{"id":14,"entrez_name":"BRAF","entrez_id":673,"name":"V600E AMPLIFICATION","description":"Amplification of BRAF V600E has been shown to confer resistance to MEK inhibitors. For more information on the V600 locus, see the V600E entry.","evidence_items":[{"id":48,"text":"COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244) resistant. The mechanim of this resistence was shown to be amplification of the BRAF V600E gene.","disease":"Colorectal Cancer","doid":"9256","citation":"Corcoran et al., 2010, Sci Signal","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21098728","pubmed_id":"21098728","drugs":[{"id":22,"name":"AZD6244","pubchem_id":null}],"rating":4,"evidence_level":"D","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]},{"id":13,"entrez_name":"BRAF","entrez_id":673,"name":"V600E/V600M","description":"A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response.","evidence_items":[{"id":49,"text":"A single patient with BRAF V600E/V600M bi-allelic mutation responded to the V600E drug dabrafenib.","disease":"Melanoma","doid":"1909","citation":"Ponti et al., 2012, J Hematol Oncol","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23031422","pubmed_id":"23031422","drugs":[{"id":12,"name":"Dabrafenib","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[{"id":4,"name":"Other V600's","description":"While BRAF V600E is nearly ubiquitous in many cancer types, other V600 variants have also been observed and studied to a lesser degree. At first approximation, many of these variants seem to behave similarly to V600E, and treatment with dabrafenib has been shown to be effective. "}]},{"id":15,"entrez_name":"BRAF","entrez_id":673,"name":"V600M","description":"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.","evidence_items":[{"id":50,"text":"Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.","disease":"Melanoma","doid":"1909","citation":"Ponti et al., 2013, J. Clin. Pathol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23463675","pubmed_id":"23463675","drugs":[{"id":12,"name":"Dabrafenib","pubchem_id":null}],"rating":5,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"7:140453137-140453137 (C-\u003eT)","variant_origin":"Somatic"}],"variant_groups":[{"id":4,"name":"Other V600's","description":"While BRAF V600E is nearly ubiquitous in many cancer types, other V600 variants have also been observed and studied to a lesser degree. At first approximation, many of these variants seem to behave similarly to V600E, and treatment with dabrafenib has been shown to be effective. "}]},{"id":16,"entrez_name":"BRAF","entrez_id":673,"name":"V600R","description":"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.","evidence_items":[{"id":51,"text":"Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.","disease":"Melanoma","doid":"1909","citation":"Ponti et al., 2013, J. Clin. Pathol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23463675","pubmed_id":"23463675","drugs":[{"id":12,"name":"Dabrafenib","pubchem_id":null}],"rating":5,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"7:140453136-140453137 (AC-\u003eCT)","variant_origin":"Somatic"}],"variant_groups":[{"id":4,"name":"Other V600's","description":"While BRAF V600E is nearly ubiquitous in many cancer types, other V600 variants have also been observed and studied to a lesser degree. At first approximation, many of these variants seem to behave similarly to V600E, and treatment with dabrafenib has been shown to be effective. "}]},{"id":18,"entrez_name":"CCND1","entrez_id":595,"name":"AMPLIFICATION","description":"CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.","evidence_items":[{"id":54,"text":"Inceased copy number of CCND1 is associated with poorer overall survival.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Gautschi et al., 2007, Lung Cancer","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/17070615","pubmed_id":"17070615","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]},{"id":19,"entrez_name":"CCND1","entrez_id":595,"name":"EXPRESSION","description":"CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.","evidence_items":[{"id":55,"text":"Three studies have found no significant survival impact for CCND1 in lung cancer.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Gautschi et al., 2007, Lung Cancer","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/17070615","pubmed_id":"17070615","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Does Not Support","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":56,"text":"Three studies have associated CCND1 expression with poorer survival.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Gautschi et al., 2007, Lung Cancer","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/17070615","pubmed_id":"17070615","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]},{"id":20,"entrez_name":"CCND1","entrez_id":595,"name":"OVEREXPRESSION","description":"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.","evidence_items":[{"id":57,"text":"Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer.","disease":"Breast Cancer","doid":"1612","citation":"Arnold et al., 2005, J. Clin. Oncol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/15961768","pubmed_id":"15961768","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Diagnostic","clinical_significance":"Positive","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":58,"text":"In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis.","disease":"Breast Cancer","doid":"1612","citation":"Arnold et al., 2005, J. Clin. Oncol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/15961768","pubmed_id":"15961768","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":59,"text":"Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.","disease":"Head And Neck Squamous Cell Carcinoma","doid":"5520","citation":"Thomas et al., 2005, Int J Exp Pathol","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/16309541","pubmed_id":"16309541","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":60,"text":"Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.","disease":"Mantle Cell Lymphoma","doid":"0050746","citation":"Jares et al., 2007, Nat. Rev. Cancer","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/17891190","pubmed_id":"17891190","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]},{"id":21,"entrez_name":"CCND2","entrez_id":894,"name":"OVEREXPRESSION","description":"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.","evidence_items":[{"id":61,"text":"Cyclin D2 overexpression is associated with poor prognosis in gastric cancers.","disease":"Stomach Cancer","doid":"10534","citation":"Takano et al., 1999, J. Pathol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/10547574","pubmed_id":"10547574","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":62,"text":"Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers.","disease":"Stomach Cancer","doid":"10534","citation":"Takano et al., 1999, J. Pathol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/10547574","pubmed_id":"10547574","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":63,"text":"Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers.","disease":"Stomach Cancer","doid":"10534","citation":"Takano et al., 1999, J. Pathol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/10547574","pubmed_id":"10547574","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":64,"text":"Cyclin D2 overexpression is associated with vascular invasion by cancer cells in gastric cancers.","disease":"Stomach Cancer","doid":"10534","citation":"Takano et al., 1999, J. Pathol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/10547574","pubmed_id":"10547574","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]},{"id":22,"entrez_name":"CCND2","entrez_id":894,"name":"PROMOTER DEMETHYLATION","description":"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.","evidence_items":[{"id":65,"text":"CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II.","disease":"Stomach Cancer","doid":"10534","citation":"Oshimo et al., 2003, Int. J. Oncol.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/14612939","pubmed_id":"14612939","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Diagnostic","clinical_significance":"Negative","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]},{"id":23,"entrez_name":"CCND3","entrez_id":896,"name":"LOSS","description":"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL.","evidence_items":[{"id":66,"text":"Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with Palbociclib (PD-0332991) significantly increased median survival.","disease":"T-cell Leukemia","doid":"715","citation":"Sawai et al., 2012, Cancer Cell","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23079656","pubmed_id":"23079656","drugs":[{"id":24,"name":"Palbociclib (PD-0332991)","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]},{"id":24,"entrez_name":"CCNE1","entrez_id":898,"name":"OVEREXPRESSION","description":"Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.","evidence_items":[{"id":67,"text":"Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times higher than those with normal cyclin E levels.","disease":"Breast Cancer","doid":"1612","citation":"Keyomarsi et al., 2002, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/12432043","pubmed_id":"12432043","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":68,"text":"Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.","disease":"Gastric Adenosquamous Carcinoma","doid":"5635","citation":"Donnellan et al., 1999, FASEB J.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/10224221","pubmed_id":"10224221","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":69,"text":"Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.","disease":"Gastric Adenosquamous Carcinoma","doid":"5635","citation":"Donnellan et al., 1999, FASEB J.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/10224221","pubmed_id":"10224221","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":70,"text":"Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.","disease":"Lung Cancer","doid":"1324","citation":"Donnellan et al., 1999, FASEB J.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/10224221","pubmed_id":"10224221","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Poor Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]},{"id":25,"entrez_name":"CDK4","entrez_id":1019,"name":"EXPRESSION","description":"CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.","evidence_items":[{"id":71,"text":"In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions.","disease":"Estrogen-receptor Positive Breast Cancer","doid":"0060075","citation":"Vora et al., 2014, Cancer Cell","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/25002028","pubmed_id":"25002028","drugs":[{"id":25,"name":"BYL719","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":72,"text":"Palbociclib has been shown to dramatically improve progression-free survival by over 18 months in patients with ER+ Breast Cancer.","disease":"Estrogen-receptor Positive Breast Cancer","doid":"0060075","citation":"Logan et al., 2013, Anticancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23898052","pubmed_id":"23898052","drugs":[{"id":26,"name":"Palbociclib","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Prognostic","clinical_significance":"Better Outcome","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[]}]